Skip to main content

Home/ WSU Virology/ Group items tagged oncolytic

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
Haram LEE

BMC Cancer | Full text | Oncolytic Targeting of Androgen-sensitive Prostate Tumor by th... - 4 views

www.biomedcentral.com/...43

vriology Oncolytic virotherapy RSV

shared by Haram LEE on 27 Sep 12 - No Cached
Trevor F liked it
  • Haram LEE on 27 Sep 12
     
    Oncolytic virotherapy for cancer treatment utilizes viruses for selective infection and death of cancer cells without any adverse effect on normal cells. We previously reported that the human respiratory syncytial virus (RSV) is a novel oncolytic virus against androgen-independent PC-3 human prostate cancer cells.
  • ...2 more comments...
  • Haram LEE on 27 Sep 12
     
    Is there any other virus can using for Oncolytic virotherapy? - Oncolytic viruses identified to date are: adenovirus, reovirus, herpes simplex virus (HSV), Newcastle disease virus (NDV), vaccinia virus, myxoma virus, influenza virus, measles virus, coxsackievirus and vesicular stomatitis virus (VSV) (Anticancer oncolytic activity of respiratory syncytial virus., http://www.ncbi.nlm.nih.gov/pubmed?term=Anti-cancer%20oncolytic%20activity%20of%20respiratory%20syncytial%20virus)
  • Haram LEE on 27 Sep 12
     
    Why also using xenograft, not only for cell-culture method? - A human prostate tumor xenograft model (30) was used to examine the oncolytic function of RSV in vivo (Figure 2). -We also investigated the efficacy of intraperitoneally (I.P) delivered RSV for causing tumor regression and determined that intraperitoneally injected RSV also rendered significant reduction in the tumor growth compared to the growth of control, medium-treated tumors (Figure 2c). The significant tumor regression by intraperitoneally delivered RSV is shown in Figure 2d. Similar results were obtained with tumors grown in the dorsal flank (Supplementary Figure S2). Therefore, the RSV-responsive restriction of tumor growth at two sites (ear and flank) demonstrates the versatility of RSV in conferring oncolysis in vivo at different anatomical regions. (Anticancer oncolytic activity of respiratory syncytial virus., http://www.ncbi.nlm.nih.gov/pubmed?term=Anti-cancer%20oncolytic%20activity%20of%20respiratory%20syncytial%20virus)
  • Haram LEE on 27 Sep 12
     
    How Oncolytic virus control the inflammation? - Oncolytic virus treatment induced at least a twofold increase or decrease in the expression of 50 genes relative to expression in the PBS-treated tumors (Supplementary Table 1, available online). Of these 50 genes, 48 displayed an increase in expression in the oncolytic virus - treated tumors compared with the controltreated tumors, suggesting that oncolytic virus treatment induced an inflammatory response - To confirm the role of the immune response in oncolytic virus - induced vascular hyperpermeability, we evaluated changes in oncolytic virus - induced vascular leakage in tumor-bearing rats that had been treated with cyclophosphamide before oncolytic virus injection. In addition to its immunosuppressive effects, cyclophosphamide blocks infl ammation and reduces viral clearance, both of which increase the propagation of oncolytic viruses, thereby enhancing therapeutic effi cacy of oncolytic viruses. (Effect of Tumor Microenvironment Modulation on the Efficacy of Oncolytic Virus Therapy, http://www.ncbi.nlm.nih.gov/pubmed?term=Effect%20of%20Tumor%20Microenvironment%20Modulation%20on%20the%20Efficacy%20of%20Oncolytic%20Virus%20Therapy)
  • Haram LEE on 27 Sep 12
Haram LEE

Oncolytic Virus-Mediated Manipulation of DNA Damage Responses: Synergy With Chemotherap... - 0 views

jnci.oxfordjournals.org/...42.short

virology Oncolytic Virus DNA Damage Responses

shared by Haram LEE on 11 Sep 12 - No Cached
  • Haram LEE on 11 Sep 12
     
    There is a new scientific discovery about the "oncolytic virus" which means attack a tumor. That discovery said that RSV-respiratory syncytial virus- is an oncolytic virus which can attack cancer tumor selectively. But, that paper has not published yet, so i find a paper about the oncolytic virus.
  • Haram LEE on 11 Sep 12
     
    http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0002917 is also Oncolytic Virus. Title : Systemic Therapy for Cervical Cancer with Potentially Regulatable Oncolytic Adenoviruses
  • Sarah Muncy on 17 Sep 12
     
    It's really cool to think that we're spending all this time and money on nanotechnology in the medical field, when we already have biological nanotechnology at our fingertips-- if we can learn to use them (viruses) anyway. Perhaps in 100 years a virion will refer to a virus that can heal a cell vs. infect it.
Casey Finnerty

Research - A Neuro-Oncology Laboratory at Northwestern University in Chicago - 1 views

www.lesniaklab.com/research.html

virotherapy

shared by Casey Finnerty on 12 Oct 16 - No Cached
  • Most adenoviruses that have been historically used for gene therapy have been based on serotype 5 (AdWT). Unfortunately, expression of the primary receptor for Ad5 (the coxsackie-adenovirus receptor, CAR) is highly variable on cancer cells. In fact, several studies have demonstrated a resistance of malignant glioma to adenoviral vectors, a finding that was subsequently attributed to the quantitative deficiency of CAR on brain tumor cells.
  • First, we tested a variety of tumor specific promoters and identified survivin (S) as an excellent tumor specific promoter for transcriptional control of E1a, a gene essential for CRAd replication (J Neurosurg 104:583, 2006; Cancer Biol Ther 6:679, 2007).
  • Based on the above date data, we then created a novel oncolytic adenoviral vector which utilizes the survivin promoter and binds to heparan sulfate proteoglycans expressed on malignant brain tumors and named this new vector CRAd-S-pk7 (Hum Gene Ther 18:589, 2007).
    • Casey Finnerty
      Casey Finnerty on 12 Oct 16
       
      How specific is the binding/tropism? HS is fairly widespread throughout the body.
  • ...6 more annotations...
  • Second, we have identified several receptors that are over-expressed on brain tumor cells and created a series of pseudotyped Ad5 vectors that recognize these receptors
  • Our studies with CRAd-S-pk7 indicate that the virus provides the highest level of viral replication and tumor oncolysis in glioma cell lines. At the same time, we observed minimal viral replication and toxicity in normal human brain. Injection of CRAd-S-pk7 inhibited xenograft brain tumor growth by more than 300%.
  • We were the first group in the country to show that human mesenchymal stem cells can be effectively loaded with a replication competent virus and effectively deliver it to an experimental glioma model
  • When oncolytic vectors are loaded onto stem cells, the virus effectively "hides" from the immune system for an extended period of time. The ability of stem cells to suppress the anti-viral immune response in a permissive and tumor-bearing animal model is the subject of one of our latest manuscript
  • Finally, to further enhance the therapeutic efficacy of stem cells, we have optimized them to specifically traffic to intracranial tumors via genetic modification with single-chain antibodies against antigens expressed on gliomas
  • Our latest work in this area supports the development of neural stem cell based cell carriers for oncolytic virotherapy
1 - 4 of 4
Showing 20▼ items per page